In a patient with metastatic breast cancer to the brain who has a 3.5 cm cerebellar lesion with edema and has started dexamethasone, should we repeat magnetic resonance imaging in six weeks and consult radiation oncology for whole‑brain radiation therapy, or consult neurosurgery and radiation oncology for localized radiation (e.g., stereotactic radiosurgery)?

Consult Neurosurgery and Radiation Oncology for Localized Radiation (Stereotactic Radiosurgery)

For a 3.5 cm cerebellar brain metastasis from breast cancer with edema, you should immediately consult both neurosurgery and radiation oncology to evaluate for surgical resection followed by stereotactic radiosurgery (SRS) to the resection cavity, rather than repeating MRI in 6 weeks or proceeding with whole-brain radiation therapy (WBRT). This approach prioritizes survival, functional independence, and cognitive preservation.

Rationale for Immediate Multidisciplinary Consultation

Why Surgery Should Be Considered First

The 2022 Society for Neuro-Oncology (SNO) guidelines 1 explicitly identify bulky metastases (typically >3-4 cm) as a standard indication for craniotomy. Your patient's 3.5 cm cerebellar lesion meets this threshold. The guidelines emphasize that:

• Large tumors with mass effect benefit more from surgery than from radiation alone
• For bulky tumors, the stereotactic radiation dose that can be safely administered is limited due to constraints from surrounding brain tissue, often compromising control
• Posterior fossa location (cerebellum) constitutes a surgical indication because of the risk of obstructive hydrocephalus 2
• Surgery allows rapid steroid tapering, which is particularly relevant if immunotherapy is being considered 2

The 2021 EANO-ESMO guidelines 2 reinforce that large BMs (>3 cm diameter) causing raised intracranial pressure or neurological impairment warrant surgical consideration, especially in the posterior fossa.

Why Not Delay with Repeat MRI in 6 Weeks

Waiting 6 weeks is inappropriate for a symptomatic 3.5 cm cerebellar lesion with edema. The 2022 SNO guidelines 1 recommend brain MRIs every 2-3 months after initial treatment, not before treatment of a newly diagnosed symptomatic lesion. The guidelines state that earlier scans should be prompted by new/worsening symptomatology—which your patient already has (edema requiring dexamethasone).

Delaying definitive treatment risks:

• Progressive mass effect and potential herniation
• Prolonged steroid exposure with associated toxicities
• Obstructive hydrocephalus (given cerebellar location)
• Neurological deterioration before permanent sequelae develop

Why Not Whole-Brain Radiation Therapy

WBRT is not the preferred initial approach for a single large brain metastasis in a patient with good performance status. The 2022 ASCO-SNO-ASTRO guideline 3 and 2021 EANO-ESMO guidelines 2 establish that:

• SRS has become standard of care for patients with newly diagnosed brain metastases and good performance status due to good tumor control and decreased risk of cognitive deficits compared to WBRT 4
• WBRT after SRS or surgery reduces intracranial relapses but fails to improve overall survival or duration of functional independence and is associated with detrimental effects on neurocognitive function 2
• Conventional WBRT is now considered only for patients in whom surgery or SRS is not recommended, such as those with several large brain metastases and limited survival expectancy 4

The 2022 HER2-positive breast cancer brain metastasis guideline 5 specifically recommends for patients with a single brain metastasis: surgery with postoperative radiation, SRS alone, or WBRT plus memantine and hippocampal avoidance (± SRS)—with surgery plus postoperative radiation listed first for large, symptomatic lesions.

Recommended Treatment Algorithm

Step 1: Immediate Multidisciplinary Evaluation

Consult both neurosurgery and radiation oncology now to assess:

• Surgical resectability and risk
• Patient's performance status and systemic disease control
• Molecular characteristics of the breast cancer (HER2 status, hormone receptor status)

Step 2: Surgical Resection (If Feasible)

Surgery is strongly indicated for this patient because:

• Tumor size >3 cm
• Cerebellar location with risk of obstructive hydrocephalus
• Symptomatic edema requiring steroids
• Surgery provides immediate decompression and allows rapid steroid taper

The 2022 SNO guidelines 1 note that among patients with neurologic symptoms caused by brain metastases despite steroids, neither radiation nor systemic therapy can reliably and quickly decompress affected areas before permanent sequelae develop—surgery is typically indicated.

Step 3: Post-Operative Stereotactic Radiosurgery to Resection Cavity

After surgical resection, SRS to the resection cavity should be offered rather than WBRT. The 2022 ASCO guideline 3 states: "SRS alone to the surgical cavity should be offered to patients with one to two resected brain metastases."

The 2021 EANO-ESMO guidelines 2 cite two randomized trials:

• Brown et al.: Post-operative SRS versus WBRT showed no difference in overall survival, but cognitive decline was more frequent after WBRT
• Mahajan et al.: Post-operative SRS versus observation showed significantly improved freedom from local recurrence with SRS

For a 3.5 cm resection cavity, risk-adapted fractionation over 3-5 fractions is encouraged rather than single-fraction treatment 2.

Step 4: Surveillance and Systemic Therapy Considerations

• Serial MRI every 2-3 months for the first 1-2 years after treatment 1
• Continue dexamethasone at the lowest effective dose (4-8 mg/day for moderate symptoms) and taper as edema improves 1
• For HER2-positive breast cancer with brain metastases, consider tucatinib plus capecitabine plus trastuzumab or trastuzumab deruxtecan if systemic disease is progressive 5
• Do not switch systemic therapy if systemic disease is not progressive at the time of brain metastasis diagnosis 5

Critical Pitfalls to Avoid

1. Do not delay treatment for repeat imaging in a symptomatic patient with a large cerebellar lesion
2. Do not use WBRT as first-line therapy for a single resectable brain metastasis in a patient with good performance status—this sacrifices cognitive function without survival benefit
3. Do not continue high-dose dexamethasone indefinitely—the FDA label 6 recommends 10 mg IV initially followed by 4 mg every 6 hours until symptoms subside, then taper over 5-7 days. Prolonged use (>3 weeks) increases risk of complications 1
4. Do not assume breast cancer brain metastases are unresectable—even with multiple metastases, surgery may be indicated for large symptomatic lesions causing mass effect 2

Special Considerations for Breast Cancer

The 2022 HER2-positive breast cancer guideline 5 notes that median survival for patients with ER-positive, HER2-positive breast cancer and good performance status, even with multiple brain metastases and extracranial disease, is approximately 3 years. This favorable prognosis supports aggressive local therapy to preserve quality of life and cognitive function.

If the patient has asymptomatic brain metastases and HER2-positive disease, systemic therapy with tucatinib-based regimens may be considered with delayed local therapy until intracranial progression 5. However, your patient is symptomatic with edema, making immediate local therapy appropriate.